Welcome to Polly’s


Thursday, October 22, 2 PM - 6 PM EDT


We are excited to bring to you Polly’s first User Group Meeting. Join us on this virtual event featuring product demos and updates, panel discussion on FAIR Principles, and user-led presentations demonstrating real world use cases. Our goal is to help users learn from each other, our experts and industry leaders. We look forward to your valuable feedback for future product development.


Aaron Arvey

Director Machine Learning,Third Rock Ventures

Avi Ma'ayan

Director, Mount Sinai Center for Bioinformatics

John F. Conway

Chief Visioneer Officer, 20/15 Visioneers

Ewy Mathé

Director Of Informatics, NCATS

Kate Yen

Founder, CEO at Auron Therapeutics

Gautham Sridharan

Senior Scientist, Alnylam Pharmaceuticals

Kelly Stewart Marsh

Senior Scientist, Agios Pharmaceuticals

Timothy Garrett

Associate Professor, University of Florida

Shawn Davidson

Associate Research Scholar/Lecturer, Lewis-Sigler Institute for Integrative Genomics

Hans K Ghayee,

Clinical Assistant Professor; VA Section Chief, UFL

John Janiszewski

Research Scientist, NIH/NCATS

Bart Ghesquière

Professor, KU Leuven

Thuc Le

Assistant Professor, UCLA

Richard Kibbey

Scientific Co-Founder, Elucidata

Abhishek Jha

CEO & Founder, Elucidata

Swetabh Pathak

Co-Founder, Elucidata

Sony Kadavan

VP Engineering, Elucidata

James Martin

VP Business & Market Development, Elucidata

Shefali Lathwal

Lead Scientist, Elucidata

Surbhi Poddar

Product Manager, Elucidata


  • 2-2.10 pm

    Welcome and Opening message

    Abhishek Jha, Ph.D., Co-Founder and CEO, Elucidata

  • 2.10-2.25 pm

    Elucidata and Polly: Helping You Resurrect Your Data

    James Martin, Vice President, Business and Market Development, Elucidata

    While scientific data may be readily available, oftentimes it is not usable. Elucidata leverages the power of Polly, its SaaS enabled scientific data management and analysis platform, to empower scientists and data scientists to generate key insights from public or proprietary data. Elucidata ensures superior customer experience via technology and service, improving speed and quality of research results. Come take a quick tour of Elucidata offerings, and see how they add value to your bioinformatics enterprise.

  • 2.25-2.45 pm

    What's new on Polly? FAIR molecular data for ML

    Swetabh Pathak, Co-Founder, Elucidata

    Garbage in Garbage out concept states that healthy data is imperative to generating accurate models. Reports suggest over 80% of the time consumed in big data analysis is spent on making data machine-accessible and machine-readable. In this session, we will discuss how data engineering systems can enable complex querying of multi-omic data repositories and drive discovery efforts.

  • 2.45-3.30 pm

    Diving into data lakes: A Polly Data lake demo

    Shefali Lathwal, Ph.D., Lead Scientist, Elucidata

    Data are at the heart of our customers’ research. We have kept data at the heart of Polly too. In this session, we will look at data lakes in depth (pun-intended) and do a live demonstration of what data can do for you on Polly.

  • 3.30-4.15 pm

    Meet our Customers!

    Kate Yen, CEO, Auron Therapeutics: Target Identification for AML with Polly

    Gautham Sridharan, Senior Scientist, Alnylam Pharmaceuticals

    Kelly Marsh, Senior Scientist, Agios Pharmaceuticals

    Thuc Le, Assistant Professor, UCLA

  • 4-4.15 pm

    A FAIR Assessment: Harvesting Harmonized Datasets to Identify Targets

    Dr. Richard Kibbey, Scientific Co-founder, Elucidata

    Value of a collection of datasets is greater than the sum of its individual parts. We are integrating data across tissues, data types, and disease states. In this session we will present a use case to identify targets to improve metabolism and set a vision for how this approach can be applied to other scientific questions.

  • 4-4.30 pm

    DIY novel methods for FAIR analysis: Polly Applications Demo

    Surbhi Poddar, Product Manager, Elucidata

    Polly provides an infrastructure that allows users to create their own workflow from a suite of tools both proprietary and public that facilitates easy insight generation. In this session we will look at how the platform enables teams of biologists and bioinformaticians with easy to create and use custom analysis workflows employing FAIR principles.

  • 4-4.30 pm

    Engineering the Polly platform

    Sony Kadavan, Vice President, Engineering, Elucidata

    Polly has grown from a collection of apps to a platform over the past years. Let's do a deep dive into the technology behind Polly. The insights you get could give you more ideas to better adapt the platform for your needs and, at the same time, set the stage for our next wave of the platform.

  • 4.30-5.10 pm

    Panel discussion: What does FAIR mean for the industry?

    Avi Ma’ayan (Panel Chair, Moderator), Director, Mount Sinai

    Ewy Mathé, Director of Informatics, NCATS

    John Conway, Chief Visioneer Officer, 20/15 Visioneers

    Aaron Arvey, Director Machine Learning, Third Rock Ventures

    Abhishek Jha, Ph.D., Co-Founder and CEO, Elucidata

    FAIR is an initiative by NIH. Good data management is not a goal in itself, but rather is the key conduit leading to knowledge discovery and innovation, and to subsequent data and knowledge integration and reuse by the community after the data publication process. This session will discuss the role of FAIR multi-omics data in data-driven drug discovery and what data FAIRification means for our industry.

  • 5-5.30 pm

    Meet our Customers!

    John Janiszewski, Scientist, NCATS

    Timothy Garrett, Professor, University of Florida

    Bart Ghesquiere, Associate Professor, KU Leuven

    Shawn Davidson, Associate Research Scholar, Princeton University

    Hans Ghayee, Clinical Assistant Professor, University of Florida: Targeting Metastatic Pheochromocytoma/Paraganglioma

  • 5.30-6 pm

    Polly’s Journey Forward: Roadmap

    Swetabh Pathak, Co-Founder, Elucidata

    Molecular data will grow both in variety and volume for the foreseeable future. The barriers to get great insights will also shift as has happened in other fields as well. Seeing the data centric Polly is exciting, let’s also imagine the future of biomedical data and how Polly will adapt to it.